ArticleDiscover oncology2025
Nrf2 functions as a biomarker and therapeutic target in lung cancer based on bibliometric analysis and molecular mechanisms.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLung cancer is one of the malignant tumors with high morbidity and mortality worldwide. Nuclear factor E2-ralated factor 2 (Nrf2), a critical antioxidant transcription factor, has been identified to play a significant role in the pathogenesis, progression and chemoresistance of lung cancer through its dysregulated activation. The present investigation sought to enhance our understanding of the global research landscape concerning Nrf2 in lung cancer by employing a bibliometric methodology.
methodsThe present study retrieved relevant articles and reviews concerning Nrf2 in lung cancer from the Web of Science Core Collection and Scopus databases. A comprehensive bibliometric analysis was conducted utilizing a suite of tools including Microsoft Excel, Python, CiteSpace, VOSviewer, R (bibliometrix), and Charticulator to evaluate various aspects such as publication productivity, contributing nations, affiliated institutions, prominent authors, influential journals, co-cited references, and thematic keywords.
resultsThe study encompassed 1931 publications, showing a marked rise in citations from 2002 to 2025. China dominated the publication landscape, with several leading institutions contributing. Professors Masayuki Yamamoto and Shyam Biswal were identified as key contributors. Cancer Research was the most prolific journal. Nrf2 played a central role in lung cancer research, with research hotspots evolving from basic studies to clinical treatment strategies and increasing interest in specific lung cancer subtypes, reflecting the multidimensional and interdisciplinary development of the field.
conclusionResearch on Nrf2 in lung cancer has shifted from basic cell typing to studies of oxidation and programmed cell death, and it is time to dissect upstream regulators and create targeted Nrf2 modulators for personalized treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.